803 related articles for article (PubMed ID: 25516189)
1. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis.
Siedner MJ; Ng CK; Bassett IV; Katz IT; Bangsberg DR; Tsai AC
Clin Infect Dis; 2015 Apr; 60(7):1120-7. PubMed ID: 25516189
[TBL] [Abstract][Full Text] [Related]
2. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda.
Mutimura E; Addison D; Anastos K; Hoover D; Dusingize JC; Karenzie B; Izimukwiye I; Mutesa L; Nsanzimana S; Nash D;
AIDS; 2015 Jan; 29(1):67-76. PubMed ID: 25562492
[TBL] [Abstract][Full Text] [Related]
3. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.
Lawn SD; Myer L; Bekker LG; Wood R
BMC Infect Dis; 2006 Mar; 6():59. PubMed ID: 16551345
[TBL] [Abstract][Full Text] [Related]
4. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis.
Mugglin C; Estill J; Wandeler G; Bender N; Egger M; Gsponer T; Keiser O;
Trop Med Int Health; 2012 Dec; 17(12):1509-20. PubMed ID: 22994151
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.
Breton G; Lewden C; Spire B; Salmon D; Brun-Vézinet F; Duong M; Allavena C; Leport C; Salamon R;
HIV Med; 2007 Apr; 8(3):164-70. PubMed ID: 17461860
[TBL] [Abstract][Full Text] [Related]
6. Incorporating loss to follow-up in estimates of survival among HIV-infected individuals in sub-Saharan Africa enrolled in antiretroviral therapy programs.
Verguet S; Lim SS; Murray CJ; Gakidou E; Salomon JA
J Infect Dis; 2013 Jan; 207(1):72-9. PubMed ID: 23100567
[TBL] [Abstract][Full Text] [Related]
7. Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment.
Bwire R; Nagelkerke NJ; Borgdorff MW
Trop Med Int Health; 2006 Oct; 11(10):1567-75. PubMed ID: 17002731
[TBL] [Abstract][Full Text] [Related]
8. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis.
Ndawinz JD; Chaix B; Koulla-Shiro S; Delaporte E; Okouda B; Abanda A; Tchomthe S; Mboui E; Costagliola D; Supervie V
J Antimicrob Chemother; 2013 Jun; 68(6):1388-99. PubMed ID: 23391713
[TBL] [Abstract][Full Text] [Related]
10. Interventions to improve the rate or timing of initiation of antiretroviral therapy for HIV in sub-Saharan Africa: meta-analyses of effectiveness.
Fox MP; Rosen S; Geldsetzer P; Bärnighausen T; Negussie E; Beanland R
J Int AIDS Soc; 2016; 19(1):20888. PubMed ID: 27507249
[TBL] [Abstract][Full Text] [Related]
11. Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis.
Seyler C; Messou E; Gabillard D; Inwoley A; Alioum A; Anglaret X
AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1338-47. PubMed ID: 18184075
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of the WHO clinical staging system for defining eligibility for ART in sub-Saharan Africa: a systematic review and meta-analysis.
Munthali C; Taegtmeyer M; Garner PG; Lalloo DG; Squire SB; Corbett EL; Ford N; MacPherson P
J Int AIDS Soc; 2014; 17(1):18932. PubMed ID: 24929097
[TBL] [Abstract][Full Text] [Related]
13. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
14. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America.
; Keiser O; Anastos K; Schechter M; Balestre E; Myer L; Boulle A; Bangsberg D; Touré H; Braitstein P; Sprinz E; Nash D; Hosseinipour M; Dabis F; May M; Brinkhof MW; Egger M
Trop Med Int Health; 2008 Jul; 13(7):870-9. PubMed ID: 18373510
[TBL] [Abstract][Full Text] [Related]
16. Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial.
Rosen S; Maskew M; Fox MP; Nyoni C; Mongwenyana C; Malete G; Sanne I; Bokaba D; Sauls C; Rohr J; Long L
PLoS Med; 2016 May; 13(5):e1002015. PubMed ID: 27163694
[TBL] [Abstract][Full Text] [Related]
17. Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries.
Nash D; Wu Y; Elul B; Hoos D; El Sadr W;
AIDS; 2011 Jul; 25(12):1523-33. PubMed ID: 21750418
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated with Timing of Initiation of Antiretroviral Therapy among HIV-1 Infected Adults in the Niger Delta Region of Nigeria.
Ogoina D; Finomo F; Harry T; Inatimi O; Ebuenyi I; Tariladei WW; Afolayan AA
PLoS One; 2015; 10(5):e0125665. PubMed ID: 25933356
[TBL] [Abstract][Full Text] [Related]
19. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.
Stringer JS; Zulu I; Levy J; Stringer EM; Mwango A; Chi BH; Mtonga V; Reid S; Cantrell RA; Bulterys M; Saag MS; Marlink RG; Mwinga A; Ellerbrock TV; Sinkala M
JAMA; 2006 Aug; 296(7):782-93. PubMed ID: 16905784
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.
May M; Boulle A; Phiri S; Messou E; Myer L; Wood R; Keiser O; Sterne JA; Dabis F; Egger M;
Lancet; 2010 Aug; 376(9739):449-57. PubMed ID: 20638120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
